Vitamin C Urinary Loss in Fabry Disease: Clinical and Genomic Characteristics of Vitamin C Renal Leak
Ifechukwude Ebenuwa(National Institute of Diabetes and Digestive and Kidney Diseases), Mark Levine(University of Iowa), Peter Eck(University of Manitoba), Hongbin Tu(National Institutes of Health), Sebastian J. Padayatty(National Institutes of Health), Kenneth J. Wilkins(National Institutes of Health), Yaohui Wang(Nanjing University of Chinese Medicine), Raphael Schiffmann(Texas Christian University), David F. Moore(National Institutes of Health), Pierre-Christian Violet(National Institute of Diabetes and Digestive and Kidney Diseases)
Cited by 7
Related Papers
Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat
|New England Journal of Medicine|2016|555
Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy
|Nephrology Dialysis Transplantation|2009|366
Effect of Vitamin C, Thiamine, and Hydrocortisone on Ventilator- and Vasopressor-Free Days in Patients With Sepsis
|JAMA|2021|277
Generalisable long COVID subtypes: findings from the NIH N3C and RECOVER programmes
|EBioMedicine|2022|176